Study of Patritumab Deruxtecan With Other Anticancer Agents in Participants With HER2 Positive Breast Cancer That Has Spread and Cannot Be Surgically Removed (MK-1022-009) (NCT06686394)
🩺 Plain-English Summary (8th-Grade Level)
Researchers want to learn if patritumab deruxtecan (MK-1022) can treat certain breast cancers. The breast cancers being studied are HER2 positive unresectable locally advanced or metastatic (the cancer has spread to other parts of the body). The goals of this study are to learn: * About the safety and how well people tolerate of patritumab deruxtecan * How many people have the cancer respond (get smaller or go away) to treatment
Who can join: To join this study, participants generally need to meet the listed inclusion criteria (10 items) and avoid the listed exclusions (13 items).
Location: University of Colorado Anschutz Medical Campus ( Site 0057) — Aurora, Colorado
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistCheck every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).
Usually NOT eligible if any of the following apply:
- Exclusion Criteria: The main exclusion criteria include but are not limited to the following:
- Uncontrolled or significant cardiovascular disease
- History of (noninfectious) pneumonitis/interstitial lung disease (ILD) that required steroids or has current pneumonitis/interstitial lung disease
- Has clinically severe respiratory compromise
- Has any history of or evidence of any current leptomeningeal disease
- Has clinically significant corneal disease
- Evidence of ongoing uncontrolled systemic bacterial, fungal, or viral infection
- HIV infected participants with a history of Kaposi's sarcoma and/or Multicentric Castleman's Disease
- Known additional malignancy that is progressing or has required active treatment within the past 3 years
- Evidence of spinal cord compression or brain metastases
- Has an active infection requiring systemic therapy
- Concurrent active HBV and HCV infection
🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.
📍 All Participating Trial Locations (18 Sites)
- University of Colorado Anschutz Medical Campus ( Site 0057) — Aurora, Colorado
- Dana-Farber Cancer Institute ( Site 0050) — Boston, Massachusetts
- Rutgers Cancer Institute of New Jersey ( Site 0052) — New Brunswick, New Jersey
- Prisma Health - Upstate (ITOR)_Edenfield ( Site 0053) — Greenville, South Carolina
- Inova Schar Cancer Institute ( Site 0051) — Fairfax, Virginia
- Kingston General Hospital ( Site 0061) — Kingston, Ontario
- Princess Margaret Cancer Centre ( Site 0001) — Toronto, Ontario
- Centre Hospitalier de l'Université de Montréal ( Site 0004) — Montreal, Quebec
- Jewish General Hospital ( Site 0003) — Montreal, Quebec
- Rambam Health Care Campus ( Site 0011) — Haifa,
- Rabin Medical Center ( Site 0012) — Petah Tikva,
- Sheba Medical Center ( Site 0010) — Ramat Gan,
- Nagoya City University Hospital ( Site 0020) — Nagoya, Aichi-ken
- Seoul National University Hospital ( Site 0030) — Seoul,
- Asan Medical Center ( Site 0031) — Seoul,
- University College London Hospital ( Site 0041) — London, Camden
- The Beatson West of Scotland Cancer Centre ( Site 0043) — Glasgow, Glasgow City
- St Bartholomew s Hospital ( Site 0040) — London, London, City of
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.